163 related articles for article (PubMed ID: 32299084)
1. Pharmacological Acromegaly Treatment: Cost-Utility and Value of Information Analysis.
Leonart LP; Riveros BS; Krahn MD; Pontarolo R
Neuroendocrinology; 2021; 111(4):388-402. PubMed ID: 32299084
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain.
Peral C; Cordido F; Gimeno-Ballester V; Mir N; Sánchez-Cenizo L; Rubio-Rodríguez D; Rubio-Terrés C
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):105-114. PubMed ID: 31055976
[No Abstract] [Full Text] [Related]
3. Cost-Utility of Acromegaly Pharmacological Treatments in a French Context.
Brue T; Chanson P; Rodien P; Delemer B; Drui D; Marié L; Juban L; Salvi L; Henocque R; Raverot G
Front Endocrinol (Lausanne); 2021; 12():745843. PubMed ID: 34690933
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
Bonert V; Mirocha J; Carmichael J; Yuen KCJ; Araki T; Melmed S
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32754748
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil.
Valentim J; Passos V; Mataveli F; Calabró A
Arq Bras Endocrinol Metabol; 2008 Dec; 52(9):1452-60. PubMed ID: 19197453
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of somatostatin analogues in the treatment of acromegaly.
Orlewska E; Stępień R; Orlewska K
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):15-25. PubMed ID: 30122081
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.
Barnes JI; Lin JK; Gupta D; Owens DK; Goldhaber-Fiebert JD; Kunz PL
J Natl Compr Canc Netw; 2020 Sep; 18(9):1200-1209. PubMed ID: 32886901
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of acromegaly treatments: a systematic review.
Leonart LP; Borba HHL; Ferreira VL; Riveros BS; Pontarolo R
Pituitary; 2018 Dec; 21(6):642-652. PubMed ID: 30159696
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
Biermasz NR; Roelfsema F; Pereira AM; Romijn JA
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):223-34. PubMed ID: 19527094
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China].
Xuan JW; Zhang ZY; Wang YF; Mao ZG; Lu YJ; Wang RZ
Zhonghua Yi Xue Za Zhi; 2017 Mar; 97(10):765-769. PubMed ID: 28316158
[No Abstract] [Full Text] [Related]
11. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
[TBL] [Abstract][Full Text] [Related]
12. Optimizing somatostatin analog therapy in acromegaly: long-acting formulations.
Gilroy JJ; James RA
Treat Endocrinol; 2002; 1(3):149-54. PubMed ID: 15799207
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome.
Margusino-Framiñán L; Pertega-Diaz S; Pena-Bello L; Sangiao-Alvarellos S; Outeiriño-Blanco E; Pita-Gutierrez F; Pita-Fernandez S; Cordido F
Eur J Intern Med; 2015 Nov; 26(9):736-41. PubMed ID: 26300269
[TBL] [Abstract][Full Text] [Related]
14. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
15. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
17. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
[TBL] [Abstract][Full Text] [Related]
18. Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis.
Leonart LP; Ferreira VL; Tonin FS; Fernandez-Llimos F; Pontarolo R
Value Health; 2018 Jul; 21(7):874-880. PubMed ID: 30005760
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy for acromegaly: future role for pasireotide?
Ben-Shlomo A
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):35-41. PubMed ID: 25732640
[TBL] [Abstract][Full Text] [Related]
20. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly.
Abrams P; Alexopoulou O; Abs R; Maiter D; Verhelst J
Eur J Endocrinol; 2007 Nov; 157(5):571-7. PubMed ID: 17984236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
